Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Italy shows the way on AED policy, as draft legislation promises major market hike

This article was originally published in Clinica

Executive Summary

Wide-ranging Italian plans to improve the efficiency of public health services, with a focus on preventive health, promise a major increase in the supply of automated external defibrillators (AEDs). All amateur and professional sports clubs would be required by law to install AEDs and ensure their appropriate access and use, according to the latest amendments of the draft so-called Balduzzi Decree, which has been approved by the cabinet of ministers for further parliamentary scrutiny. Italy has long been a model of cardiac screening of young sportspeople, but a spate of high-profile cases of cardiac arrest among both amateur and professional sportsmen, in Italy and other countries, have thrust AED access policy onto the preventive health agenda internationally.

You may also be interested in...



The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

Syngene COO On Delivering Cost Gains For mRNA Products

Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company' capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT099382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel